Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Verastem Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VSTM
Nasdaq
8731
https://www.verastem.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Verastem Inc
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
- Apr 18th, 2024 8:05 pm
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 4th, 2024 11:30 am
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
- Mar 18th, 2024 11:00 am
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
- Mar 14th, 2024 8:05 pm
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
- Mar 11th, 2024 11:30 am
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
- Mar 5th, 2024 10:27 pm
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
- Mar 5th, 2024 9:30 pm
Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc
- Feb 15th, 2024 8:12 am
Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM)
- Feb 7th, 2024 10:02 pm
3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024
- Feb 7th, 2024 12:15 pm
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
- Jan 29th, 2024 12:00 pm
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
- Jan 22nd, 2024 1:15 pm
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
- Jan 18th, 2024 9:00 pm
Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
- Jan 11th, 2024 12:00 pm
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
- Dec 18th, 2023 12:00 pm
3 Off-the-Beaten-Path Stocks Poised for Substantial Growth
- Dec 13th, 2023 2:08 pm
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
- Dec 13th, 2023 12:00 pm
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
- Dec 3rd, 2023 9:17 pm
All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy
- Nov 22nd, 2023 5:00 pm
New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
- Nov 13th, 2023 12:00 pm
Scroll